{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000535","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.169294+00:00","generated_at":"2026-05-28T06:20:02.979350+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M","bullets":["Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).","GAAP net loss $10.7M ($0.26 loss/share); adjusted loss $0.04/share vs $0.08 loss prior year.","Adjusted EBITDA $3.1M (vs $0.0M); FY25 guidance raised to $1-3M from loss of $2.5M-$0; adjusted loss per share guidance improved to $0.34-0.38.","Received FDA 510(k) clearance for NanoKnife prostate tissue ablation and CPT Category I codes for IRE (effective Jan 2026).","Cash $54.1M; operating cash flow $2.5M; $1.1M used on share repurchases in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000535","json":"https://secwatch.observer/filing/0001140361-25-000535.json","markdown":"https://secwatch.observer/filing/0001140361-25-000535.md","text":"https://secwatch.observer/filing/0001140361-25-000535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125000535/0001140361-25-000535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125000535/ef20041243_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:20:02.979350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}